➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
Colorcon
Baxter
Johnson and Johnson
Mallinckrodt

Last Updated: January 28, 2021

DrugPatentWatch Database Preview

METHYLTESTOSTERONE Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Methyltestosterone, and what generic alternatives are available?

Methyltestosterone is a drug marketed by Heather, Impax Labs Inc, Impax Labs, Lilly, Purepac Pharm, Pvt Form, Tablicaps, Usl Pharma, Inwood Labs, Kv Pharm, Lannett, Parke Davis, Watson Labs, and West Ward. and is included in twenty-seven NDAs.

The generic ingredient in METHYLTESTOSTERONE is methyltestosterone. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the methyltestosterone profile page.

US ANDA Litigation and Generic Entry Outlook for Methyltestosterone

A generic version of METHYLTESTOSTERONE was approved as methyltestosterone by IMPAX LABS on December 31st, 1969.

  Start Trial

Drug patent expirations by year for METHYLTESTOSTERONE
Recent Clinical Trials for METHYLTESTOSTERONE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Fundação de Amparo à Pesquisa do Estado de São PauloPhase 4
Federal University of São PauloPhase 4
Solvay PharmaceuticalsPhase 2

See all METHYLTESTOSTERONE clinical trials

Pharmacology for METHYLTESTOSTERONE
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists
Medical Subject Heading (MeSH) Categories for METHYLTESTOSTERONE

US Patents and Regulatory Information for METHYLTESTOSTERONE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
West Ward METHYLTESTOSTERONE methyltestosterone TABLET;ORAL 084331-002 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Tablicaps METHYLTESTOSTERONE methyltestosterone TABLET;ORAL 085270-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
West Ward METHYLTESTOSTERONE methyltestosterone TABLET;ORAL 084642-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Watson Labs METHYLTESTOSTERONE methyltestosterone TABLET;ORAL 080933-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Heather METHYLTESTOSTERONE methyltestosterone CAPSULE;ORAL 084967-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Lannett METHYLTESTOSTERONE methyltestosterone TABLET;ORAL 087092-001 Nov 5, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Moodys
Boehringer Ingelheim
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.